Drug Trial Radar · NCT05524571
Study to Assess Batoclimab in Participants With Active Thyroid Eye Disease
Last checked: Nov 19, 2026Latest source record: Apr 1, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
86
Actual
Start
Jan 5, 2023
Primary completion
Feb 3, 2026
Study completion Mar 3, 2026
Sponsor
- Lead sponsor
- Immunovant Sciences GmbHIndustry
- Sponsor type
- Industry
- First posted
- Sep 1, 2022
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To evaluate the efficacy of batoclimab 680 milligrams (mg) subcutaneous (SC) once a week (QW) for 12 weeks followed by 340 mg SC QW for 12 weeks versus placebo on proptosis responder rate at Week 24.
Conditions
- Thyroid Eye Disease
Interventions
BatoclimabDrug
Batoclimab is a fully human anti-neonatal fragment crystallizable receptor (FcRn) monoclonal antibody
PlaceboDrug
Matching Placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of proptosis respondersTime frame: At Week 24
Locations
45 sites in 11 countries. Site status is shown where the registry gives one.
Site Number -1520
Pasadena, California
Site Number -1517
San Francisco, California
Site Number -1514
Torrance, California
Site Number -1510
Sarasota, Florida
Site Number -1516
Louisville, Kentucky
Site Number - 1526
Livonia, Michigan
Site Number - 1513
Rochester, Minnesota
Site Number - 1512
Winston-Salem, North Carolina
Site Number - 1525
Portland, Oregon
Site Number -1515
Bellaire, Texas
Site Number - 1524
McAllen, Texas
Site Number -1519
San Antonio, Texas
Site Number - 1521
Seattle, Washington
Site Number -1511
Morgantown, West Virginia
Site Number - 1518
Milwaukee, Wisconsin
Site Number - 7565
Sydney, Australia
Site Number -4671
Bruges, Belgium
Site Number - 4672
Brussels, Belgium
Site Number - 4673
Brussels, Belgium
Site Number -4670
Ghent, Belgium
Site Number - 4674
Liège, Belgium
Site Number - 6603
Mainz, Rhineland-Palatinate, Germany
Site Number - 7550
Budapest, Hungary
Site Number - 7551
Pécs, Hungary
Site Number - 7552
Pécs, Hungary
Site Number -9301
Ogre, Latvia
Site Number -9300
Riga, Latvia
Site Number - 9302
Ventspils, Latvia
Site Number - 7570
Christchurch, New Zealand
Site Number - 7572
Hamilton, New Zealand
Site Number -1990
San Juan, Puerto Rico
Site Number - 9203
Bratislava, Slovakia
Site Number - 9200
Bratislava, Slovakia
Site Number - 9201
Bratislava, Slovakia
Site Number - 9202
Trenčín, Slovakia
Site Number -3602
Barcelona, Spain
Site Number - 3605
Barcelona, Spain
Site Number -3601
Madrid, Spain
Site Number -3604
Madrid, Spain
Site Number -3600
Santiago de Compostela, Spain
Showing 40 of 45 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.